Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mabro

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Bulletin Du Cancer|April 22, 1999
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]M Mabro, P K Granisétron
La Revue De Medecine Interne|April 14, 2000
[Aspirin against cancer]M Mabro, A de Gramont
Drug Safety|December 20, 1999
A risk-benefit assessment of amifostine in cytoprotectionM Mabro, S Faivre, E Raymond
Journal of Oncology|April 17, 2010
Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal CancerC Louvet, T André, E Gamelin, et al.
La Revue De Medecine Interne|November 26, 1999
[Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients]M Mabro, V Gilles-Amar, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancerF Maindrault-Goebel, C Tournigand, T André, et al.
Bulletin Du Cancer|April 26, 2000
[Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2 doses]M Mabro, R Cohn, L Zanesco, et al.
British Journal of Cancer|April 20, 2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patientsM Mabro, P Artru, T André, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2002
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancerJ Taïeb, P Artru, B Baujat, et al.
La Revue De Medecine Interne|January 28, 2004
[Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]N Perez, C Tournigand, M Mabro, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Bulletin Du Cancer|April 22, 1999
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]M Mabro, P K Granisétron
La Revue De Medecine Interne|April 14, 2000
[Aspirin against cancer]M Mabro, A de Gramont
Drug Safety|December 20, 1999
A risk-benefit assessment of amifostine in cytoprotectionM Mabro, S Faivre, E Raymond
Journal of Oncology|April 17, 2010
Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal CancerC Louvet, T André, E Gamelin, et al.
La Revue De Medecine Interne|November 26, 1999
[Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients]M Mabro, V Gilles-Amar, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancerF Maindrault-Goebel, C Tournigand, T André, et al.
Bulletin Du Cancer|April 26, 2000
[Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2 doses]M Mabro, R Cohn, L Zanesco, et al.
British Journal of Cancer|April 20, 2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patientsM Mabro, P Artru, T André, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2002
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancerJ Taïeb, P Artru, B Baujat, et al.
La Revue De Medecine Interne|January 28, 2004
[Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]N Perez, C Tournigand, M Mabro, et al.
Pageof 2